Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1974
mi
from 91732
Macon, GA
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1974
mi
from 91732
Macon, GA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2126
mi
from 91732
Savannah, GA
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2126
mi
from 91732
Savannah, GA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1724
mi
from 91732
Evergreen Park, IL
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1724
mi
from 91732
Evergreen Park, IL
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1401
mi
from 91732
Shreveport, LA
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1401
mi
from 91732
Shreveport, LA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1558
mi
from 91732
Farmington, MO
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1558
mi
from 91732
Farmington, MO
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2356
mi
from 91732
Bethlehem, PA
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2356
mi
from 91732
Bethlehem, PA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2134
mi
from 91732
Uniontown, PA
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2134
mi
from 91732
Uniontown, PA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1923
mi
from 91732
Knoxville, TN
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1923
mi
from 91732
Knoxville, TN
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1252
mi
from 91732
Corsicana, TX
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1252
mi
from 91732
Corsicana, TX
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1184
mi
from 91732
San Antonio, TX
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1184
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1217
mi
from 91732
Temple, TX
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1217
mi
from 91732
Temple, TX
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
573
mi
from 91732
Salt Lake City, UT
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
333
mi
from 91732
Peoria, AZ
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
333
mi
from 91732
Peoria, AZ
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
7530
mi
from 91732
Liverpool,
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
7530
mi
from 91732
Liverpool,
Click here to add this to my saved trials
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated:  12/31/1969
Davita Clinical Research, DN
808
mi
from 91732
Lakewood, CO
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated: 12/31/1969
Davita Clinical Research, DN
808
mi
from 91732
Lakewood, CO
Click here to add this to my saved trials
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated:  12/31/1969
Orlando Clinical Research Center
2185
mi
from 91732
Orlando, FL
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated: 12/31/1969
Orlando Clinical Research Center
2185
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
1793
mi
from 91732
Indianapolis, IN
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated:  12/31/1969
DaVita Clinical Research
1509
mi
from 91732
Minneapolis, MN
A Study of LY2928057 in Hemodialysis Participants
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Status: Enrolling
Updated: 12/31/1969
DaVita Clinical Research
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Contrast Nephropathy and Nitrates
Contrast Nephropathy and Nitrates
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Medical Center
2324
mi
from 91732
Miami Beach, FL
Contrast Nephropathy and Nitrates
Contrast Nephropathy and Nitrates
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Medical Center
2324
mi
from 91732
Miami Beach, FL
Click here to add this to my saved trials
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
Non-invasive MR Imaging Diagnosis of Transplant Rejection
Status: Enrolling
Updated:  12/31/1969
Lucile Packard Childrens Hospital
328
mi
from 91732
Stanford, CA
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
Non-invasive MR Imaging Diagnosis of Transplant Rejection
Status: Enrolling
Updated: 12/31/1969
Lucile Packard Childrens Hospital
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Click here to add this to my saved trials
A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial
Status: Enrolling
Updated:  12/31/1969
Fresenius Medical Care North America
2569
mi
from 91732
Waltham, MA
A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial
Status: Enrolling
Updated: 12/31/1969
Fresenius Medical Care North America
2569
mi
from 91732
Waltham, MA
Click here to add this to my saved trials
A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial
Status: Enrolling
Updated:  12/31/1969
DaVita Clinical Research
1509
mi
from 91732
Minneapolis, MN
A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial
Status: Enrolling
Updated: 12/31/1969
DaVita Clinical Research
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [¹⁴C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis
Status: Enrolling
Updated:  12/31/1969
DaVita Clinical Research Center
1509
mi
from 91732
Minneapolis, MN
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [¹⁴C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis
Status: Enrolling
Updated: 12/31/1969
DaVita Clinical Research Center
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital
2375
mi
from 91732
Philadelphia, PA
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
Can a Targeted Screen-and-treat Program for Chronic Kidney Disease Improve Blood Pressure (BP) Management Among Persons at High Risk for Complications ?
Status: Enrolling
Updated:  12/31/1969
San Francisco Veteran Affairs Medical Center
358
mi
from 91732
San Francisco, CA
Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
Can a Targeted Screen-and-treat Program for Chronic Kidney Disease Improve Blood Pressure (BP) Management Among Persons at High Risk for Complications ?
Status: Enrolling
Updated: 12/31/1969
San Francisco Veteran Affairs Medical Center
358
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1831
mi
from 91732
Montgomery, AL
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1831
mi
from 91732
Montgomery, AL
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
353
mi
from 91732
Tempe, AZ
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
353
mi
from 91732
Tempe, AZ
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1466
mi
from 91732
Sherwood, AR
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1466
mi
from 91732
Sherwood, AR
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
106
mi
from 91732
Bakersfield, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
106
mi
from 91732
Bakersfield, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
113
mi
from 91732
Chula Vista, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
113
mi
from 91732
Chula Vista, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
7
mi
from 91732
Covina, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
7
mi
from 91732
Covina, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
11
mi
from 91732
Downey, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
11
mi
from 91732
Downey, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
25
mi
from 91732
Fountain Valley, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
25
mi
from 91732
Fountain Valley, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
22
mi
from 91732
Hawthorne, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
22
mi
from 91732
Hawthorne, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
Inglewood, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
Inglewood, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
36
mi
from 91732
Laguna Hills, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
36
mi
from 91732
Laguna Hills, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
16
mi
from 91732
Lakewood, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
16
mi
from 91732
Lakewood, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
15
mi
from 91732
Lynwood, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
15
mi
from 91732
Lynwood, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
25
mi
from 91732
Northridge, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
25
mi
from 91732
Northridge, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
350
mi
from 91732
Oakland, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
350
mi
from 91732
Oakland, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
9
mi
from 91732
Pasadena, CA
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
9
mi
from 91732
Pasadena, CA
Click here to add this to my saved trials